Alzheimer's Association Clinical Practice Guideline on the use of blood‐based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings
Rattachement africain : se, us, es, nl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE AND SCOPE: A panel of clinicians, subject-matter experts, and guideline methodologists convened by the Alzheimer's Association conducted a systematic review and formulated evidence-based recommendations for using blood-based biomarkers (BBMs) in the diagnostic workup of suspected Alzheimer's disease (AD) within specialized care settings. The scope focuses on individuals with objective cognitive impairment, including those with mild cognitive impairment (MCI) or dementia, who are undergoing evaluation by providers trained and experienced in memory disorders, where AD is the suspected underlying etiology. METHODS: The panel conducted a systematic review to assess the diagnostic accuracy of BBMs in detecting AD pathology. The BBMs of interest included plasma phosphorylated-tau (p-tau) and amyloid-beta (Aβ) tests measuring the following analytes: p-tau217, ratio of p-tau217 to non-p-tau217 ×100 (%p-tau17), p-tau181, p-tau231, and ratio of Aβ42 to Aβ40. The reference standard tests included cerebrospinal fluid (CSF) AD biomarkers, amyloid positron emission tomography (PET), or neuropathology. The panel applied the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach to assess the certainty of the evidence and the GRADE evidence-to-decision (EtD) Framework to develop its recommendations. RECOMMENDATIONS: The key recommendations in this Clinical Practice Guideline (CPG) are: (1) BBM tests with ≥90% sensitivity and ≥75% specificity can be used as a triaging test and (2) BBM tests with ≥90% sensitivity and specificity can serve as a substitute for amyloid PET imaging or CSF AD biomarker testing in patients with cognitive impairment presenting to specialized care for memory disorders. The panel cautions users of this guideline that there is significant variability in diagnostic test accuracy and many commercially available BBM tests do not meet these thresholds, especially using a single cutoff. Additionally, these tests do not serve as a substitute for comprehensive clinical evaluation by a healthcare professional and should be used only as part of a full diagnostic workup of patients with cognitive impairment presenting to specialized care settings, and with careful consideration of pretest probability of AD pathology. CONCLUSIONS AND PRACTICAL IMPLICATIONS: This CPG provides performance-based, brand-agnostic recommendations for the use of BBMs in the diagnostic workup of suspected AD within specialized care settings. By linking recommendations to a systematic review and associated living updates, and using a robust and transparent methodology, the guideline ensures scientific rigor, adaptability, and sustained relevance as evidence evolves. Clinicians are encouraged to stay informed about emerging paradigms-such as biomarker combinations or ratios and multi-threshold testing-that may further refine the diagnostic accuracy of BBMs as the field evolves.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Alzheimer's Association Clinical Practice Guideline on the use of blood‐based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings
- Date Crossref
- 01/07/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Lund University pays non établi dans la noticeUniversité ou école supérieure
-
Skåne University Hospital pays non établi dans la noticeÉtablissement de santé
-
Duke University pays non établi dans la noticeUniversité ou école supérieure
-
Durham VA Medical Center pays non établi dans la noticeÉtablissement de santé
-
Mayo Clinic pays non établi dans la noticeÉtablissement de santé
-
Pasqual Maragall Foundation pays non établi dans la noticeOrganisation à but non lucratif
-
Barcelonaβeta Brain Research Center pays non établi dans la noticeStructure de recherche
-
Hospital Del Mar pays non établi dans la noticeÉtablissement de santé
-
University of California San Diego pays non établi dans la noticeUniversité ou école supérieure
-
University of Pittsburgh pays non établi dans la noticeUniversité ou école supérieure
-
University of Pittsburgh Medical Center pays non établi dans la noticeÉtablissement de santé
-
Eastern Virginia Medical School pays non établi dans la noticeUniversité ou école supérieure
Lund University, Skåne University Hospital et Duke University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.